Pharmacokinetics of antithymocyte globulin in the treatment of childhood aplastic anemia / 中华实用儿科临床杂志

ABSTRACT

Objective To investigate the pharmacokinetics of antithymocyte globulin(ATG) in the treatment of childhood aplastic anemia(AA).Methods Six cases of of childhood AA treated with rabbit ATG (R-ATG,Genzyme company,USA and Fresenius company,Germany)were in the study.Enzyme-linked immunosorbent assay (ELISA) was used to detect the concentrations of ATG in plasma during the treatment period of the first day to the 5th day,and during the 7th,21th,35th,60th and 90th after the treatment finished respectively(all 12 time nodes).The pharmacokinetic data was detect with the Practical Pharmacokinetics-program(3P97).Results The peak levels of ATG concentrations in plasma(30-32 mg/L)were reached at the third to forth day during the treatment period,and then gradually descended to about half of the peak level in the 21st day(16-18 mg/L),and the microcomponent of ATG in plasma could be detected in the 90th day after the therapy.There were not evident difference of plasma concentrations in every time nodes,the peak levels,and pharmacokinetic data including the drug half-life,area under the plasma concentration-time curve (AUC) between the 2 forms of R-ATG (Genzyme company,USA and Fresenius company,Germany).The therapy effective rate in the 6 cases AA of this group was 66.7％ in the followed-up for mean 12 months.Conclusions Successfully set up the techniques to detect the pharmacokinetics of ATG in the treatment of childhood AA,will help to research the relationship between the pharmacokinetics with the side effects and outcomes of ATG in the treatment of AA.